EIF4EBP1 and cancer: Such high levels of activated Akt that allows cancer cells to evade apoptosis, coupled with incomplete inhibition of 4E-BP1 proves to be a toxic combination that lead to cancer progression in patients thereby limiting use of rapamycin/raplogs in cancer treatment.